Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 2:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 215 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Natesto Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Multimodality Intervention for Function and Metabolism in SCI

NCT03576001
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Testosterone Undecanoate, hybrid exercise
Drug · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
19 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 28, 2026, 2:09 PM EDT
Completed Phase 4 Interventional Results available

Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters

NCT03203681
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
Natesto
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 28, 2026, 2:09 PM EDT
Recruiting Phase 2 Interventional

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

NCT07142551
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 28, 2026, 2:09 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®

NCT01096329
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 28, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

Time to Eugonadal Range, Time to Steady State and Drying Time

NCT01228071
View directory record Official record
Conditions
Male Hypogonadism
Interventions
testosterone gel 2%
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Tucson, Arizona • Middlebury, Connecticut • Oviedo, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 28, 2026, 2:09 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions

NCT02110368
View directory record Official record
Conditions
Primary Hypogonadism, Hypogonadotropic Hypogonadism
Interventions
Testosterone Topical Gel, 1.62% Metered Pump, AndroGel (testosterone gel) 1.62% Metered-Dose Pump
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 28, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of Testosterone Cypionate in Hypogonadal Males

NCT03792477
View directory record Official record
Conditions
Hypogonadism
Interventions
Test formulation, Reference formulation
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
DeLand, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 28, 2026, 2:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

TRADE-Testosterone Replacement and Dutasteride Effectiveness

NCT00194675
View directory record Official record
Conditions
Hypogonadism, Benign Prostatic Hyperplasia
Interventions
Dutasteride, Testosterone gel, Placebo dutasteride
Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 28, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

NCT03516812
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment, Survey Administration, Testosterone Enanthate, Testosterone Cypionate
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 28, 2026, 2:09 PM EDT
Completed Phase 4 Interventional

TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY

NCT03325647
View directory record Official record
Conditions
Klinefelter Syndrome
Interventions
Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution, Placebo injectable saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
31 Days to 90 Days · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 28, 2026, 2:09 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Effect of Testosterone Replacement on Exercise Capacity in Hypogonadal Men After a Recent Myocardial Infarction

NCT02803073
View directory record Official record
Conditions
Hypogonadism, Acute Myocardial Infarction: Rehabilitation Phase
Interventions
Testosterone, Normal Saline
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Odessa, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 28, 2026, 2:09 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial

NCT07742553
View directory record Official record
Conditions
Spinal Cord Injury, Spinal Cord Injuries, Injuries, Spinal Cord, Spinal Cord Contusion, Spinal Cord Trauma, Trauma, Nervous System, Wounds and Injuries, Spinal Cord Compression, Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male
Interventions
testosterone cypionate, finasteride, placebo injection, placebo pill
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
4
States / cities
Aurora, Colorado • Gainesville, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 28, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men

NCT02697188
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone undecanoate, Testosterone enanthate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Los Angeles, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 28, 2026, 2:09 PM EDT
Terminated Early Phase 1 Interventional Results available

Testosterone for Penile Rehabilitation After Radical Prostatectomy

NCT00848497
View directory record Official record
Conditions
Hypogonadism, Erectile Dysfunction
Interventions
Testim®, Placebo Testim®, Viagra®
Drug · Other
Lead sponsor
Mohit Khera
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 28, 2026, 2:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phlebotomy Study of Testosterone Undecanoate

NCT02670343
View directory record Official record
Conditions
Hypogonadism
Interventions
Oral Testosterone Undecanoate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 28, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

NCT02722278
View directory record Official record
Conditions
Hypogonadism
Interventions
Oral Testosterone Undecanoate, Axiron Testosterone Topical Solution
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Northbrook, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 28, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men

NCT01699178
View directory record Official record
Conditions
Male Hypogonadism
Interventions
Oral testosterone undecanoate, Transdermal testosterone gel (AndroGel)
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Calera, Alabama • Huntsville, Alabama + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 28, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Influence of Male Hormones on Regional Fat Metabolism

NCT01160328
View directory record Official record
Conditions
Obesity
Interventions
Leuprolide, Testosterone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 28, 2026, 2:09 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

The Effects of Long Term Cyclic Testosterone Administration on Muscle Function and Bone in Older Men

NCT01417364
View directory record Official record
Conditions
Sarcopenia
Interventions
Testosterone enanthate, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 75 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 28, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial

NCT04685993
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
LPCN 1144
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Roseville, California • Ocoee, Florida • Las Vegas, Nevada + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 28, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men

NCT00467870
View directory record Official record
Conditions
Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
Interventions
Testosterone Undecanoate 750 mg, Testosterone Undecanoate 1000 mg
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 28, 2026, 2:09 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Metabolic Effects of Steroids in Obese Men

NCT00983554
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Anastrazole, Testosterone, Dutasteride, GnRH antagonist
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
24 Years to 51 Years · Male only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2011 · Synced Oct 28, 2026, 2:09 PM EDT
Recruiting Phase 2 Interventional

Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism

NCT04798469
View directory record Official record
Conditions
Opioid Use, Pain, Hypogonadism, Male
Interventions
Testosterone Undecanoate 250 MG/ML, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 28, 2026, 2:09 PM EDT
Withdrawn Phase 2 Interventional

Testosterone for Fatigue in Men With MS

NCT03000127
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
AndroGel 1 % Topical Gel, Placebos
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 28, 2026, 2:09 PM EDT